Enliven Therapeutics, Inc. Common Stock

ELVNNASDAQUSD
44.23 USD
0.00 (0.00%)🟢PRE MARKET (AS OF 07:06 AM EDT)
🟢Market: OPEN
Open?$44.23
High?$44.25
Low?$44.12
Prev. Close?$44.25
Volume?144
Avg. Volume?1.5M
VWAP?$44.22
Rel. Volume?0.00x
Bid / Ask
Bid?$37.91 × 100
Ask?$50.24 × 100
Spread?$12.33
Midpoint?$44.08
Valuation & Ratios
Market Cap?2.6B
Shares Out?60.9M
Float?45.4M
Float %?76.5%
P/E Ratio?N/A
P/B Ratio?5.76
EPS?-$1.73
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?28.66Strong
Quick Ratio?28.66Strong
Cash Ratio?5.97Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
83/100
P/E?
N/A
P/B?
5.76FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
-21.3CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
-22.6%WEAK
ROA?
-21.8%WEAK
Cash Flow & Enterprise
FCF?$-70459000
Enterprise Value?$2.5B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Employees
60
Market Cap
2.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-02-24
Address
6200 LOOKOUT ROAD
BOULDER, CO 80301
Phone: 720-647-8519